We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ProQR Therapeutics NV (PRQR) EUR0.04

Sell:$1.75 Buy:$1.90 Change: $0.015 (0.83%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.015 (0.83%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.015 (0.83%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Contact details

Zernikedreef 9
2333 CK
+31 (854) 894932

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$149.29 million
Shares in issue:
84.25 million
US dollar

Key personnel

  • Daniel De Boer
    Chief Executive Officer, Founder, Executive Director
  • Jurriaan Dekkers
    Chief Financial Officer
  • Sheila Sponselee
    Chief People and Operations Officer
  • Gerard Platenburg
    Chief Scientific Officer, Executive Director
  • Rene Beukema
    Chief Corporate Development Officer, General Counsel, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.